Mar 10, 2015 9:42 pm EDT Heat Biologics, Inc. Announces Pricing of Public Offering of $10,660,000 of Common Stock
Mar 09, 2015 8:00 am EDT Heat Biologics, Inc. Receives US FDA Fast Track Designation for HS-410 (Vesigenurtacel L) in Combination With BCG for the Treatment of Non-Muscle Invasive Bladder Cancer
Feb 23, 2015 8:00 am EST Heat Biologics, Inc. to Host Key Opinion Leader Meeting on February 26 in New York City
Feb 18, 2015 6:00 am EST Heat Biologics, Inc. and OncoSec Medical Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms
Feb 11, 2015 8:00 am EST Heat Biologics Presents Positive Preclinical Data on a Novel Approach to Combination Immunotherapy at the Keystone Symposia on Tumor Immunology
Jan 26, 2015 8:00 am EST Heat Biologics, Inc. Presents Positive Immunological Data on HS-410 in Non-Muscle Invasive Bladder Cancer at the 7th Annual Phacilitate Immunotherapy Forum 2015